At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Treatment of Brain Metastases From Breast Cancer With Eribulin Mesylate
In Brief
A Phase 2 clinical trial evaluating Eribulin Mesylate, MRI, and 2 other interventions for Metastatic Breast Cancer and Brain Metastases. Completed, enrolled 9 participants across 2 sites.
Detailed Summary
Subjects are asked to take part in a clinical research study that tests Eribulin, a new drug. Eribulin is an investigational (experimental) anti-cancer agent that has not been approved by the Food and Drug Administration (FDA) for use in patients with brain metastases. Eribulin is FDA approved for use in patients with metastatic breast cancer but the effect it may or may not have on brain metastases has not been studied.
Study Details
Timeline
Interventions
Most subjects will begin eribulin mesylate at 1.4 mg/m2 administered intravenously over 2 to 5 minutes on Days 1 and 8 of a 21-day cycle.
An MRI will be completed at week 1, week 12 and every 12 weeks after cycles 4+ while on study eribulin mesylate
Zofran at 8mg orally. Given at the discretion of the treating physician
decadron at 8mg orally. Given at the discretion of the treating physician